NCT04023812CompletedNot Applicable
Real-World Molecular Testing, Treatment Patterns and Clinical Outcomes in Chinese Patients With Stage III NSCLC- A Prospective, Non-Interventional Study(MOOREA)
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- To observe treatment patterns of unresectable, stage III NSCLC
Study Overview
Brief Summary
The objectives of this study are to assess molecular testing, treatment patterns and associated clinical outcomes in Chinese patients with treatment-naïve stage III non-small cell lung cancer (NSCLC) in real world setting. This study is a prospective, non-interventional study. It is descriptive in nature and does not attempt to test any specific a priori hypotheses.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 130 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female aged 18 years or older.
- •Provision of informed consent prior to any study specific procedures.
- •Histologically or cytologically confirmed locally advanced, stage III NSCLC (according to version 8 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology; IASLC Staging Manual in Thoracic Oncology).
Exclusion Criteria
- •Enrolment in studies that prohibit any participation in this observational study.
- •Patients may be concurrently enrolled in unblinded clinical trials, but not blinded clinical trials in which the treatment being administered is unknown.
- •Prior surgery, radiotherapy or systemic therapy for NSCLC, including chemotherapy, targeted therapy, anti-angiogenesis, etc.
Outcomes
Primary Outcomes
To observe treatment patterns of unresectable, stage III NSCLC
Time Frame: Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months
Treatment received before disease progress including chemotherapy, targeted therapy, immunotherapy, anti-angiogenesis therapy and radiotherapy
Secondary Outcomes
- To estimate parameters associated with radiation pneumonitis(Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months)
- To observe molecular testing patterns of stage III NSCLC(Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months)
- To observe adjuvant treatment patterns of resectable, stage III NSCLC(Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months)
- To observe the clinical outcome of unresectable, stage III NSCLC(Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLCCarcinoma, Non-Small-Cell LungNCT02777658AstraZeneca169
Completed
Not Applicable
Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI TherapyLocally Advanced or Metastatic NSCLCNCT04207775AstraZeneca300
Enrolling By Invitation
Not Applicable
New Molecular Approaches for Diagnosis of Prosthetic Joint InfectionProsthetic Joint InfectionNCT06670885I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio70
Active, not recruiting
Phase 2
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)Metastatic Malignant NeoplasmRecurrent Malignant NeoplasmNCT02152254M.D. Anderson Cancer Center1,362
Recruiting
Phase 4
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid CancerAdvanced Thyroid Cancer Patients Who Received Target TherapyNCT06195228Fudan University800